# Atrial Fibrillation

A practical framework for confirming atrial fibrillation, defining acute stability, completing the initial evaluation, preventing thromboembolism, selecting rate or rhythm control, and identifying patients who benefit from catheter ablation or focused heart-failure management.

**Clinical question:** How should clinicians confirm, risk-stratify, and manage atrial fibrillation across acute and longitudinal care?

Updated: 2026-08-21T00:02:02.738307Z

## What matters in practice
- Confirm AF on ECG; irregularly irregular RR intervals, absent distinct P waves, and irregular atrial activity support the diagnosis.[5][6]
- Hemodynamic compromise warrants immediate direct-current cardioversion; stable patients usually undergo ventricular rate control and subsequent individualized rhythm-control assessment.[6]
- For newly diagnosed AF, obtain transthoracic echocardiography plus CBC, metabolic panel, and thyroid testing; do not order routine ischemia or pulmonary embolism testing without suggestive findings.[17]
- Assess annual thromboembolic risk with a validated score. Anticoagulation is recommended at estimated risk ≥2%/year, exemplified by CHA2DS2-VASc ≥2 in men or ≥3 in women; DOACs are preferred over warfarin absent moderate-to-severe mitral stenosis or a mechanical valve.[17]
- Dronedarone is contraindicated in permanent AF and in recent decompensated or NYHA class IV heart failure; it doubles adverse clinical risks in these populations.[1]
- In AF with HFrEF, consider arrhythmia-induced cardiomyopathy and pursue early rhythm-control evaluation; catheter ablation benefits appropriately selected patients receiving guideline-directed HF therapy.[17]

## Confirm AF and complete the first evaluation

Establish the rhythm diagnosis, identify instability, and define factors that change immediate treatment.

AF requires ECG documentation. Typical findings are irregularly irregular R-R intervals when atrioventricular conduction is intact, absent distinct repeating P waves, and irregular fibrillatory atrial activity.[5][6] Device-detected atrial high-rate episodes require visual review to distinguish AF from other atrial tachyarrhythmias, artifact, or oversensing.[5]

For newly diagnosed AF, order transthoracic echocardiography, CBC, metabolic panel, and thyroid function testing. Echocardiography informs chamber and valve assessment, ventricular function, and downstream antiarrhythmic or ablation selection; laboratory testing identifies renal, hepatic, hematologic, and thyroid factors that alter anticoagulant and antiarrhythmic choices.[17]
- Do not use AF alone as an indication for routine protocolized ischemia, acute coronary syndrome, or pulmonary embolism testing; investigate when symptoms, signs, or clinical context support those diagnoses.[17]
- If onset timing is uncertain and cardioversion is contemplated in a hemodynamically stable patient, transesophageal echocardiography is used to exclude left atrial thrombus before cardioversion.[6]

*Initial evaluation priorities in newly diagnosed atrial fibrillation.[17]*

| Question | Action | Clinical consequence |
| --- | --- | --- |
| Is AF documented? | Obtain and interpret ECG for AF features.[5][6] | Confirms diagnosis before disease-specific treatment. |
| Is the patient unstable? | Assess blood pressure, ischemia, pulmonary edema, shock, and altered perfusion. | Hemodynamic compromise prompts immediate direct-current cardioversion.[6] |
| Is there structural disease or ventricular dysfunction? | Order transthoracic echocardiography.[17] | Influences rate-control drug safety, rhythm strategy, and ablation candidacy. |
| Are reversible or treatment-modifying factors present? | Obtain CBC, metabolic panel, and thyroid function testing.[17] | Guides anticoagulant dosing, bleeding assessment, and treatment of associated conditions. |

## Stabilize first, then select rate or rhythm control

Urgency is determined by hemodynamics, not simply by a rapid ventricular response.

Most patients with new-onset or acute AF do not require immediate cardioversion. In hemodynamically stable AF, initial ventricular rate control is commonly used while clinicians address triggers, assess thromboembolic risk, and determine whether rhythm control is appropriate.[6]

For hemodynamically stable AF with rapid ventricular response and ejection fraction >40%, beta-blockers or nondihydropyridine calcium channel blockers such as diltiazem or verapamil are recommended for acute rate control. Do not administer intravenous nondihydropyridine calcium channel blockers in known moderate or severe LV systolic dysfunction, with or without decompensated heart failure.[17]
- Use direct-current cardioversion immediately for hemodynamic compromise.[6]
- For stable AF, discuss rate versus rhythm control in the context of symptoms, clinical presentation, comorbidity burden, medication profile, and patient preferences.[17]
- A lenient resting rate target below 110 beats/min produced similar cardiovascular outcomes and symptoms to a strict target below 80 beats/min in hemodynamically stable AF in the cited evidence base.[17]

*High-value acute management distinctions.[6][17]*

| Clinical state | Preferred next step | Avoid or reassess |
| --- | --- | --- |
| Hemodynamic compromise | Immediate direct-current cardioversion.[6] | Do not delay stabilization for routine longitudinal testing. |
| Stable AF with rapid ventricular response and EF >40% | Beta-blocker or diltiazem/verapamil for acute rate control.[17] | Reassess for rhythm-control indications after stabilization. |
| Rapid ventricular response with moderate/severe LV systolic dysfunction | Avoid intravenous diltiazem or verapamil.[17] | Do not assume nondihydropyridine calcium channel blockers are safe in HFrEF. |
| Uncertain duration before planned cardioversion | Use transesophageal echocardiography to exclude left atrial thrombus.[6] | Do not proceed as though onset is known. |

## Base anticoagulation on annual thromboembolic risk

AF pattern does not remove the need for risk-based stroke prevention.

Assess annual thromboembolic risk with a validated clinical score such as CHA2DS2-VASc; ATRIA and GARFIELD-AF are alternatives referenced in current U.S. performance measures.[17] Anticoagulation is recommended for estimated annual thromboembolic risk of at least 2%, illustrated by CHA2DS2-VASc ≥2 in men or ≥3 in women. Anticoagulation is reasonable at estimated risk of 1% to <2% per year.[17]

For anticoagulation candidates without moderate-to-severe rheumatic mitral stenosis or a mechanical heart valve, DOACs are recommended over warfarin to reduce mortality, stroke, systemic embolism, and intracranial hemorrhage.[17] Aspirin alone, or aspirin plus clopidogrel as an alternative to anticoagulation, is not recommended for AF stroke prevention in patients who are anticoagulation candidates.[17]
- Use warfarin rather than a DOAC for AF with rheumatic mitral stenosis or mitral stenosis of moderate or greater severity, and avoid DOACs with mechanical heart valves.[17]
- In end-stage CKD with creatinine clearance <15 mL/min or dialysis, the cited U.S. measure identifies warfarin or an evidence-based dose of apixaban as options that may be reasonable; dabigatran and edoxaban are inappropriate in this setting.[17]
- Reassess anticoagulant dose and interacting drugs as renal function, age, body weight, and medication lists change. Real-world data show frequent reduced-dose prescribing and possible undertreatment when label-based criteria are not met.[19]

*Anticoagulation decisions in atrial fibrillation.[17]*

| Situation | Action | Key limitation or exception |
| --- | --- | --- |
| Estimated thromboembolic risk ≥2%/year | Prescribe anticoagulation unless contraindicated.[17] | CHA2DS2-VASc ≥2 in men or ≥3 in women is an example threshold.[17] |
| Eligible for anticoagulation without significant mitral stenosis or mechanical valve | Prefer a DOAC over warfarin.[17] | Use drug-specific FDA labeling for dose selection. |
| Moderate/severe mitral stenosis or mechanical valve | Use warfarin rather than a DOAC.[17] | DOAC use is inappropriate in these populations.[17] |
| AF with PCI and an anticoagulation indication | Use a DOAC plus P2Y12 inhibitor and discontinue aspirin early, generally within 1 to 4 weeks.[17] | Longer triple therapy may be considered when perceived stent-thrombosis risk is high.[17] |
| AF with stable coronary disease beyond 1 year after revascularization and no stent thrombosis | Use oral anticoagulant monotherapy rather than adding single antiplatelet therapy.[17] | Document competing coronary or thrombotic indications. |

## Use rhythm control deliberately and refer for ablation when it changes outcomes

Rhythm control is increasingly early and outcome-oriented, particularly in HFrEF.

The current U.S. guideline framework emphasizes early and continued management aimed at maintaining sinus rhythm and minimizing AF burden.[18] Shared decision-making should compare rate and rhythm strategies, incorporating symptom burden, comorbidity, drug risks, procedural candidacy, and patient goals.[17]

Catheter ablation is useful for symptomatic AF when antiarrhythmic drugs are ineffective, contraindicated, not tolerated, or not preferred and rhythm control remains desired. In symptomatic or clinically significant atrial flutter, catheter ablation is also useful for symptom improvement.[17] Pulmonary vein isolation is the recommended primary lesion set for AF ablation unless a different specific trigger is identified.[17]
- In selected patients, generally younger individuals with few comorbidities and symptomatic paroxysmal AF who desire rhythm control, catheter ablation is a Class 1 first-line option to improve symptoms and reduce progression to persistent AF.[18]
- Perform AF ablation on uninterrupted therapeutic warfarin with INR 2.0-3.0, or continuous/minimally interrupted DOAC therapy.[17]
- Dronedarone is indicated to reduce AF hospitalization in patients in sinus rhythm with a history of paroxysmal or persistent AF, but is contraindicated in permanent AF and in recent decompensated or NYHA class IV heart failure.[1]

### AF with HFrEF

In new HFrEF with AF, suspect arrhythmia-induced cardiomyopathy and pursue an early, aggressive rhythm-control approach.[17] In appropriate patients with AF and HFrEF who are receiving guideline-directed therapy and have reasonable expected procedural benefit, catheter ablation improves symptoms, quality of life, ventricular function, and cardiovascular outcomes.[17]

In CASTLE-AF, catheter ablation reduced the composite of death or heart-failure hospitalization versus medical therapy in a selected HFrEF population; the review reports composite event rates of 28.5% versus 44.6%.[7] Applicability depends on patient selection, AF burden, ventricular function, comorbidity, and procedural access.[7]

*Rhythm-control drug safety issues with immediate clinical consequences.[1][17]*

| Drug or strategy | Do not use when | Operational requirement |
| --- | --- | --- |
| Flecainide or propafenone | Previous MI or significant structural heart disease, including HFrEF with LVEF ≤40%.[17] | Avoid because of worsening HF, proarrhythmia, and increased mortality risk.[17] |
| Dronedarone | Permanent AF; NYHA class IV HF; or symptomatic HF with recent decompensation requiring hospitalization.[1] | Check rhythm at least every 3 months; discontinue or cardiovert if AF recurs.[1] |
| Dofetilide | Outpatient initiation or dose escalation.[17] | Initiate or increase dose with at least 3 days of inpatient continuous ECG monitoring, creatinine-clearance calculation, and resuscitation capability.[17] |
| AF ablation | When oral anticoagulation cannot safely be managed without a compelling individualized plan. | Use uninterrupted warfarin or continuous/minimally interrupted DOAC therapy.[17] |

## Treat AF as a progressive cardiometabolic disease

Prevent recurrence, progression, and complications while monitoring treatment safety.

Lifestyle and risk-factor modification is a central component of AF management. For BMI >27 kg/m², target at least 10% weight loss; recommend moderate-to-vigorous activity totaling 210 minutes weekly; provide tobacco-cessation treatment; counsel alcohol minimization or elimination for patients pursuing rhythm control; and optimize blood pressure in patients with hypertension.[17]

AF discovered during acute medical illness or surgery should not be dismissed as transient. Patients should be counseled about recurrence risk after the acute trigger resolves; cited recurrence estimates are 42% to 68% after acute medical illness and 39% after surgery over five years.[17]
- For dronedarone, obtain rhythm surveillance at least every 3 months; discontinue the drug or cardiovert if AF is detected.[1]
- Monitor potassium and magnesium when using potassium-depleting diuretics with dronedarone, and monitor renal function periodically. A small early creatinine rise may reflect inhibited tubular secretion, but marked creatinine increase or renal failure can occur, often with heart failure or hypovolemia.[1]
- Evaluate new dyspnea or nonproductive cough for possible dronedarone pulmonary toxicity; discontinue if confirmed. Evaluate suspected hepatic injury promptly and do not restart without another explanation.[1]

*Secondary prevention targets in established AF.[17]*

| Risk domain | Action | Target or trigger |
| --- | --- | --- |
| Overweight or obesity | Offer structured weight-loss management. | BMI >27 kg/m²; ideal target ≥10% weight loss.[17] |
| Physical inactivity | Prescribe moderate-to-vigorous exercise when clinically appropriate. | 210 minutes weekly.[17] |
| Tobacco | Provide cessation counseling and guideline-directed cessation treatment. | Any cigarette smoking history in AF.[17] |
| Alcohol | Counsel minimization or elimination when rhythm control is sought. | Relevant alcohol use in AF.[17] |
| Hypertension | Optimize blood-pressure treatment. | Confirmed hypertension with AF.[17] |

## Common questions

### What is the minimum recommended initial workup for newly diagnosed AF?

Obtain a transthoracic echocardiogram, CBC, metabolic panel, and thyroid function testing. Avoid routine ischemia, ACS, or pulmonary embolism testing unless symptoms or signs suggest those disorders.[17]

### When is immediate cardioversion indicated in AF?

Immediate direct-current cardioversion is indicated for hemodynamic compromise. Most stable patients do not require immediate cardioversion and can first receive rate control and individualized rhythm-control assessment.[6]

### When should a DOAC not be used for AF stroke prevention?

Avoid DOACs with mechanical heart valves and with rheumatic or moderate-to-severe mitral stenosis; use warfarin in these settings.[17]

### When should catheter ablation be discussed in AF with HFrEF?

Discuss ablation in appropriate patients with AF and HFrEF receiving guideline-directed medical therapy when procedural benefit is reasonably expected; it can improve symptoms, ventricular function, quality of life, and cardiovascular outcomes.[17]

## References
1. These highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ.
       MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7fa41601-7fb5-4155-8e50-2ae903f0d2d6&type=display
2. DailyMed - WARFARIN SODIUM tablet — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f1c3083-91d1-488c-ad07-b198fda21da6
3. These highlights do not include all the information needed to use LACOSAMIDE TABLETS safely and effectively. See full prescribing information for LACOSAMIDE TABLETS.
 
LACOSAMIDE film coated tablet, for oral use, CV
 
Initial U.S. Approval: 2008 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8d2906e3-d059-425d-b971-29423963c2af&type=display
4. These highlights do not include all the information needed to use TADLIQ safely and effectively. See full prescribing information for TADLIQ.TADLIQ® (tadalafil) oral suspensionInitial U.S. Approval: 2003 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a909b25-3772-403e-a5fe-e4a040293fb7&type=display
5. Established atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/1
6. New-onset atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/3
7. Update on management of atrial fibrillation in heart failure: a focus on ablation | Heart — heart.bmj.com — https://heart.bmj.com/content/108/6/422
8. Risk-Guided Screening for Atrial Fibrillation Using ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079391
9. Reimagining atrial fibrillation screening beyond age-based thresholds using AI | npj Digital Medicine — www.nature.com — https://www.nature.com/articles/s41746-026-02485-w
10. Atrial fibrillation detection via contactless radio monitoring and knowledge transfer | Nature Communications — www.nature.com — https://www.nature.com/articles/s41467-025-59482-y
11. JACC: Asia: Vol 6, No 8_Part_1 — www.jacc.org — https://www.jacc.org/toc/jacc-asia/6/8_Part_1
12. Electrocardiographic diagnosis of atrial fibrillation — www.nature.com — https://www.nature.com/articles/ncpcardio0092
13. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis ... — www.ahajournals.org — https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001193
14. Atrial Fibrillation Detection Using a Novel Cardiac ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/jaha.118.009351
15. Atrial Fibrillation Screening During Routine Automated ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.123.22563
16. Management of Atrial Fibrillation in Patients 75 Years and ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2021.10.037
17. 2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2026.05.032
18. 2023 Atrial Fibrillation Guideline-at-a-Glance — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2023.10.021
19. Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-021-99818-4
20. Clinical Performance and Quality Measures of Atrial ... — academic.oup.com — https://academic.oup.com/milmed/article/191/5-6/e1033/8313926
21. Trigger-induced atrial fibrillation for the hospitalist: a review — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0953620526001810
22. An international physician survey of current ablation practices in atrial fibrillation: An AIM-AF substudy — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1547527124035057
23. Chronic Atrial Fibrillation - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/chronic-atrial-fibrillation
24. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert ... — academic.oup.com — https://academic.oup.com/europace/article/20/1/157/4158231

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.